You are here



22 Sep 2010: NorDiag has received a new order for 50 Arrow instruments for delivery in Q4-2010. This order comes in addition to the order for 30 instruments in Q3-2010, which was mentioned in NorDiag's half-year report 2010. "As a consequence of this order, our order book is now sufficient to achieve the communicated targets for Arrow in 2010. The focus is now on delivery", says CEO Mårten Wigstøl.

On  4 July 2010, NorDiag and the Korean company Seegene entered into a five-year OEM-agreement  through  which  Seegene  guaranteed  to  purchase instruments and reagents  corresponding to a value of NOK 30 million in the first 2.5 years. The agreement covers 40 per cent of the revenues  NorDiag needs on Arrow to reach a break-even quarter within 2011.

Seegene was listed on the stock exchange in Korea (KOSDAQ) on 13 September 2010 and raised USD 16.6 million in new equity in an IPO prior to the listing.

"This is an extremely exciting partner", says Wigstøl.


CEO Mårten Wigstøl      Phone: +47 911 65775

About NorDiag:

NorDiag is a biotechnology company developing, manufacturing and marketing automated solutions (instrument  and reagents) for sample preparation of DNA from  difficult biological samples. DNA diagnostics  give more rapid and precise answers, and are the fastest growing field within diagnostics. The Company's sample preparation solutions are today used in connection with STI, tuberculosis, MRSA, respiratory pathogens and viruses on instruments for large and small laboratories. NorDiag was founded in 2003 and has its headquarters in Oslo, Norway. The company has offices and laboratories in Stockholm, Sweden, in West Chester (PA), USA and in Vienna, Austria. The group has today 36.5 man-labour years. NorDiag is listed on Oslo Stock Exchange with ticker NORD.

For further information -

About Seegene Inc:

Seegene,  Inc. is a  biotechnology company specialized  in molecular diagnostics and research applications. It holds a novel detection platform named "Seeplex(R)," which sets a standard in  high-throughput and simultaneous multi-pathogen detection called "multiplexing." Seeplex(R) technology accurately detects multi-pathogens with high-throughput speed, ultimately providing the most economical basis for saving time, labor and cost. Seegene develops, manufactures and markets innovative molecular diagnostic products and services to a worldwide community. Its mission is  to maintain leadership in molecular diagnostics for infectious diseases, genetics, pharmacogenetics, and oncology, and chromosomal analyses using innovative proprietary technologies.

On 13 September 2010, the company was listed on the Korean stock exchange (KOSDAQ). The company raised USD 16.6 million in an IPO ahead of the listing. The company's implicit market value after the IPO was USD 167 million. For further information, please see or call +301-762-9066.

Read the notice in Norwegian here